# Eli Lilly & Co. (LLY) — Stock CV

Eli Lilly & Co. is a $1.05T healthcare company. Revenue grew 49.6% over the last year, it keeps 34¢ of every dollar of sales as profit, and its net debt equals ~1.9 years of free cash flow. It trades at 41.6× earnings — in the cheapest third of its own history.

> Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

## Identity

- **Ticker**: LLY
- **Sector**: Healthcare
- **Industry**: Drug Manufacturers - General
- **Headquarters**: INDIANAPOLIS, IN
- **Employees**: 50 000
- **Website**: https://www.lilly.com
- **Market cap**: $1.05T
- **Last price**: $1 177.20
- **Financial profile**: Solid

## Vitals (TTM)

- **Revenue**: $79.7B
- **Net income**: $26.7B
- **Free cash flow**: $18.2B
- **Net debt**: $35.2B
- **P/E**: 41.6
- **Revenue growth (YoY)**: 49.6%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 40 |
| Growth | 100 |
| Profitability | 100 |
| Health | 67 |
| Quality | 61 |
| Moat | 80 |

## Qualifications (beginner checklist) — 11 of 11 passed

- [x] Revenue growing — +49.6% YoY
- [x] Profitable — $26.7B TTM
- [x] Profit growing — +49.3% YoY
- [x] Generates cash — $18.2B TTM
- [x] Debt under control — ~1.9y of cash flow to repay
- [x] Established company — $1.05T market cap
- [x] Not printing shares — -1.4% shares over ~5y
- [x] Proven track record — 9/10 profitable years
- [x] Financially stable — Altman Z 7.1 — safe
- [x] Pays a dividend — yield 0.52%
- [x] Valuation not extreme — P/E 41.6

## Experience (career milestones)

- **FY2025** — Revenue crossed $50B: $65.2B for the year
- **FY2025** — Best year on record: $20.6B net income
- **2023** — Eli Lilly acquired Point Biopharma for $1.4 billion
- **May 13, 2022** — Mounjaro / Zepbound: GLP-1 franchise — the weight-loss boom makes Lilly a $1T contender
- **2018** — Lilly acquired Armo Biosciences for $1.6 billion, obtaining the white blood cell-boosting cancer…
- **FY2016** — First recorded profitable year: $2.74B net income
- **FY2016** — Revenue already above $10B: $21.2B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2014** — Lilly acquired Switzerland-based Novartis AG's animal health business for $5.4 billion in cash to…
- **2007** — Lilly acquired Icos for $2.1 billion, after raising its offer and facing opposition from…
- **2003** — Lilly introduced Cialis (tadalafil), a competitor to Viagra for erectile dysfunction developed in a…
- **1988** — Fluoxetine (Prozac), introduced in 1988, quickly became the company's best-selling product for treatment of…
- **Dec 29, 1987** — Prozac: the antidepressant that changed psychiatry
- **1955** — Lilly was the first company to mass-produce both the polio vaccine, developed in 1955 by Jonas Salk
- **1947** — Lilly became the first distributor of methadone in the United States and marketed it under the trade name…
- **1930** — Merthiolate, first introduced in 1930, was an "antiseptic and germicide" that became a U.S
- **1923** — Mass-produced insulin: the first commercial insulin — saved millions
- **May 10, 1876** — Founded by Colonel Eli Lilly: a Civil War veteran's pharma lab in Indianapolis

## Strengths

- High gross margin (83.4%)
- Strongly profitable — 33.5% net margin
- Revenue growing 49.6% year over year
- Strong cash conversion — FCF is 22.8% of revenue
- Interest covered 29.7× by operating earnings

## Watch-outs

- Loss-making in 1 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $28.3B | $5.58B | $5.95B |
| FY2022 | $28.5B | $6.24B | $5.23B |
| FY2023 | $34.1B | $5.24B | $793M |
| FY2024 | $45.0B | $10.6B | $3.76B |
| FY2025 | $65.2B | $20.6B | $8.97B |

---

Source: https://stockcv.com/LLY — derived from company filings; may be delayed or incomplete. Information, not investment advice.